Targeting the NF-E2-related factor 2 pathway: A novel strategy for glioblastoma (Review)

Oncology Reports

Volumn 32, Issue 2, 2014, Pages 443-450

  Zhu, Jianhong ^a   Wang, Handong ^a   Fan, Youwu ^a   Lin, Yixing ^a   Zhang, Li ^a   Ji, Xiangjun ^a   Zhou, Mengliang ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Glioblastoma; Mechanism; Nrf2; Targeting therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PROTEIN BCL 2; PROTEIN P53; TEMOZOLOMIDE; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT;

AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CELL MIGRATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REGULATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL; THERAPY RESISTANCE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84903219902     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3259     Document Type: Review

References (113)

1. Binello E and Germano IM: Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci 102: 1958-1966, 2011.
2. Van Meir EG, Hadjipanayis CG, Norden AD, et al: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193, 2010.
3. Kensler TW, Wakabayashi N and Biswal S: Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
4. Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49: 1603-1616, 2010.
5. Li H, Wang F, Zhang L, et al: Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell Signal 23: 1625-1632, 2011.
6. Bryan HK, Olayanju A, Goldring CE and Park BK: The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85: 705-717, 2013.
7. Livingston DM and Silver DP: Cancer: crossing over to drug resistance. Nature 451: 1066-1067, 2008. (Pubitemid 351317437)
8. Chen Q, Li W, Wan Y, et al: Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology 55: 1820-1829, 2012.
9. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
10. Newlands ES, Stevens MF, Wedge SR, et al: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23: 35-61, 1997. (Pubitemid 27273454)
11. Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597, 2000. (Pubitemid 30482092)
12. Cong ZX, Wang HD, Zhou Y, et al: Temozolomide and irradiation combined treatment-induced Nrf2 activation increases chemoradiation sensitivity in human glioblastoma cells. J Neurooncol 116: 41-48, 2014.
13. Hu XF, Yao J, Gao SG, et al: Nrf2 overexpression predicts prognosis and 5-fu resistance in gastric cancer. Asian Pac J Cancer Prev 14: 5231-5235, 2013.
14. Jiang T, Chen N, Zhao F, et al: High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer Res 70: 5486-5496, 2010.
15. Wang XJ, Sun Z, Villeneuve NF, et al: Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29: 1235-1243, 2008. (Pubitemid 351958704)
16. Chen CC, Chu CB, Liu KJ, et al: Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochem Pharmacol 86: 872-887, 2013.
17. Gao AM, Ke ZP, Shi F, et al: Chrysin enhances sensitivity of BEL7402/ADM cells to doxorubicin by suppressing PI3K/Akt/ Nrf2 and ERK/Nrf2 pathway. Chem Biol Interact 206: 100108, 2013.
18. Gao AM, Ke ZP, Wang JN, et al: Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 34: 1806-1814, 2013.
19. Kim WD, Kim YW, Cho IJ, et al: E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells. J Cell Sci 125: 1284-1295, 2012.
20. Lau A, Villeneuve NF, Sun Z, et al: Dual roles of Nrf2 in cancer. Pharmacol Res 58: 262-270, 2008.
21. Singh A, Wu H, Zhang P, et al: Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 9: 2365-2376, 2010.
22. Kim JH, Bogner PN, Ramnath N, et al: Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res 13: 3875-3882, 2007. (Pubitemid 47037594)
23. Alexander BM, Ligon KL and Wen PY: Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther 13: 569-581, 2013.
24. Caruso C, Carcaterra M and Donato V: Role of radiotherapy for high grade gliomas management. J Neurosurg Sci 57: 163-169, 2013.
25. Frosina G: DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 7: 989-999, 2009.
26. Singh A, Bodas M, Wakabayashi N, et al: Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signal 13: 1627-1637, 2010.
27. Sharma PK and Varshney R: 2-Deoxy-D-glucose and 6-aminonicotinamide- mediated Nrf2 down regulation leads to radiosensitization of malignant cells via abrogation of GSH-mediated defense. Free Radic Res 46: 14461457, 2012.
28. Zhang P, Singh A, Yegnasubramanian S, et al: Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 9: 336-346, 2010.
29. Na HK and Surh YJ: Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med 67: 353-365, 2014.
30. DeNicola GM, Karreth FA, Humpton TJ, et al: Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011.
31. Taguchi K, Motohashi H and Yamamoto M: Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16: 123-140, 2011.
32. Brigelius-Flohé R, Müller M, Lippmann D and Kipp AP: The yin and yang of nrf2-regulated selenoproteins in carcinogenesis. Int J Cell Biol 2012: 486147, 2012.
33. Lu SC: Regulation of glutathione synthesis. Mol Aspects Med 30: 42-59, 2009.
34. Balan M and Pal S: A novel CXCR3B chemokine receptor-induced growth-inhibitory signal in cancer cells is mediated through the regulation of Bach-1 protein and Nrf2 protein nuclear translocation. J Biol Chem 289: 3126-3137, 2014.
35. Yamadori T, Ishii Y, Homma S, et al: Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 31: 4768-4777, 2012.
36. Zou W, Chen C, Zhong Y, et al: PI3K/Akt pathway mediates Nrf2/ARE activation in human L02 hepatocytes exposed to low-concentration HBCDs. Environ Sci Technol 47: 12434-12440, 2013.
37. Kong B, Qia C, Erkan M, et al: Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels. Front Physiol 4: 246, 2013.
38. Ji XJ, Chen SH, Zhu L, et al: Knockdown of NF-E2-related factor 2 inhibits the proliferation and growth of U251MG human glioma cells in a mouse xenograft model. Oncol Rep 30: 157-164, 2013.
39. Crosas-Molist E, Bertran E, Sancho P, et al: The NADPH oxidase NOX4 inhibits hepatocyte proliferation and liver cancer progression. Free Radic Biol Med 69: 338347, 2014.
40. Wang Z, Li Y, Lv S and Tian Y: Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB. J Int Med Res 41: 1577-1585, 2013.
41. Singh A, Happel C, Manna SK, et al: Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest 123: 2921-2934, 2013.
42. Petrelli A, Perra A, Cora D, et al: MicroRNA/gene profiling unveils early molecular changes and nuclear factor erythroid related factor 2 (NRF2) activation in a rat model recapitulating human hepatocellular carcinoma (HCC). Hepatology 59: 228-241, 2014.
43. Rachakonda G, Sekhar KR, Jowhar D, et al: Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene 29: 3703-3714, 2010.
44. Pan H, Wang H, Zhu L, et al: The role of Nrf2 in migration and invasion of human glioma cell U251. World Neurosurg 80: 363-370, 2013.
45. Deryugina EI, Bourdon MA, Luo GX, et al: Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 110: 2473-2482, 1997. (Pubitemid 127699161)
46. Gan FF, Ling H, Ang X, et al: A novel shogaol analog suppresses cancer cell invasion and inflammation, and displays cytoprotective effects through modulation of NF-κB and Nrf2-Keap1 signaling pathways. Toxicol Appl Pharmacol 272: 852-862, 2013.
47. Zhang L, Wang N, Zhou S, et al: Propofol induces proliferation and invasion of gallbladder cancer cells through activation of Nrf2. J Exp Clin Cancer Res 31: 66, 2012.
48. Thangasamy A, Rogge J, Krishnegowda NK, et al: Novel function of transcription factor Nrf2 as an inhibitor of RON tyrosine kinase receptor-mediated cancer cell invasion. J Biol Chem 286: 32115-32122, 2011.
49. Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 411: 342-348, 2001. (Pubitemid 32467043)
50. Johnstone RW, Ruefli AA and Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 108: 153-164, 2002. (Pubitemid 34161136)
51. Bat-Chen W, Golan T, Peri I, et al: Allicin purified from fresh garlic cloves induces apoptosis in colon cancer cells via Nrf2. Nutr Cancer 62: 947-957, 2010.
52. Chen X, Liu J and Chen SY: Overexpression of Nrf2 diminishes ethanol-induced oxidative stress and apoptosis in neural crest cells by inducing an antioxidant response. Reprod Toxicol 42: 102-109, 2013.
53. Arlt A, Sebens S, Krebs S, et al: Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene 32: 4825-4835, 2013.
54. Liston P, Fong WG and Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22: 8568-8580, 2003. (Pubitemid 38019194)
55. Thomadaki H and Scorilas A: BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 43: 1-67, 2006. (Pubitemid 43379211)
56. Heasman SA, Zaitseva L, Bowles KM, et al: Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1. Oncotarget 2: 658-668, 2011.
57. Niture SK and Jaiswal AK: INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis. Cell Death Differ 18: 439-451, 2011.
58. Attardi LD: The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Mutat Res 569: 145-157, 2005.
59. Rotblat B, Melino G and Knight RA: NRF2 and p53: Januses in cancer? Oncotarget 3: 12721283, 2012.
60. Filomeni G, Piccirillo S, Rotilio G and Ciriolo MR: p38MAPK and ERK1/2 dictate cell death/survival response to different pro-oxidant stimuli via p53 and Nrf2 in neuroblastoma cells SH-SY5Y. Biochem Pharmacol 83: 1349-1357, 2012.
61. Lee YM, Auh QS, Lee DW, et al: Involvement of Nrf2-mediated upregulation of heme oxygenase-1 in mollugin-induced growth inhibition and apoptosis in human oral cancer cells. Biomed Res Int 2013: 210604, 2013.
62. Sell S: Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 51: 1-28, 2004.
63. Bollag W and Holdener EE: Retinoids in cancer prevention and therapy. Ann Oncol 3: 513-526, 1992.
64. Clarke N, Germain P, Altucci L and Gronemeyer H: Retinoids: potential in cancer prevention and therapy. Expert Rev Mol Med 6: 1-23, 2004.
65. Hansen LA, Sigman CC, Andreola F, et al: Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21: 1271-1279, 2000. (Pubitemid 30455984)
66. Leszczyniecka M, Roberts T, Dent P, et al: Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 90: 105-156, 2001. (Pubitemid 32926714)
67. Bobilev I, Novik V, Levi I, et al: The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cells. Cancer Biol Ther 11: 317-329, 2011.
68. Li K, Zhong C, Wang B, et al: Nrf2 expression participates in growth and differentiation of endometrial carcinoma cells in vitro and in vivo. J Mol Histol 45: 161-167, 2014.
69. Capaccione KM and Pine SR: The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 34: 1420-1430, 2013.
70. Wakabayashi N, Skoko JJ, Chartoumpekis DV, et al: Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by Notch signaling. Mol Cell Biol 34: 653-663, 2014.
71. Kanzaki H, Shinohara F, Kajiya M and Kodama T: The Keap1/Nrf2 protein axis plays a role in osteoclast differentiation by regulating intracellular reactive oxygen species signaling. J Biol Chem 288: 23009-23020, 2013.
72. Jayakumar S, Kunwar A, Sandur SK, et al: Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim Biophys Acta 1840: 485-494, 2014.
73. Wang XJ, Hayes JD, Henderson CJ and Wolf CR: Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha. Proc Natl Acad Sci USA 104: 19589-19594, 2007.
74. Tan KP, Kosuge K, Yang M and Ito S: NRF2 as a determinant of cellular resistance in retinoic acid cytotoxicity. Free Radic Biol Med 45: 1663-1673, 2008.
75. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
76. Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular selfdigestion. Nature 451: 1069-1075, 2008. (Pubitemid 351317450)
77. Kondo Y, Kanzawa T, Sawaya R and Kondo S: The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734, 2005. (Pubitemid 41486365)
78. Zhou Y, Wang HD, Zhu L, et al: Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line. Oncol Rep 29: 394-400, 2013.
79. Fan W, Tang Z, Chen D, et al: Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy 6: 614-621, 2010.
80. Kwon J, Han E, Bui CB, et al: Assurance of mitochondrial integrity and mammalian longevity by the p62-Keap1Nrf2-Nqo1 cascade. EMBO Rep 13: 150-156, 2012.
81. Inami Y, Waguri S, Sakamoto A, et al: Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 193: 275-284, 2011.
82. Digaleh H, Kiaei M and Khodagholi F: Nrf2 and Nrf1 signaling and ER stress crosstalk: implication for proteasomal degradation and autophagy. Cell Mol Life Sci 70: 4681-4694, 2013.
83. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001. (Pubitemid 33041634)
84. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004. (Pubitemid 39551674)
85. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003. (Pubitemid 37187480)
86. Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760, 2006. (Pubitemid 44949604)
87. Zhu J, Wang H, Sun Q, et al: Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer 13: 380, 2013.
88. Tsai JJ, Dudakov JA, Takahashi K, et al: Nrf2 regulates haematopoietic stem cell function. Nat Cell Biol 15: 309-316, 2013.
89. Wang K, Zhang T, Dong Q, et al: Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis 4: e537, 2013.
90. Cai C, Teng L, Vu D, et al: The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release. J Biol Chem 287: 33720-33732, 2012.
91. Loseva P, Kostyuk S, Malinovskaya E, et al: Extracellular DNA oxidation stimulates activation of NRF2 and reduces the production of ROS in human mesenchymal stem cells. Expert Opin Biol Ther 12 (Suppl 1): S85-S97, 2012.
92. Hoelzinger DB, Demuth T and Berens ME: Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 99: 1583-1593, 2007. (Pubitemid 351767231)
93. Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252, 2009.
94. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003. (Pubitemid 37328844)
95. Folkins C, Man S, Xu P, et al: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67: 3560-3564, 2007. (Pubitemid 46762138)
96. Zhou S, Ye W, Zhang M and Liang J: The effects of nrf2 on tumor angiogenesis: a review of the possible mechanisms of action. Crit Rev Eukaryot Gene Expr 22: 149-160, 2012.
97. Ashino T, Yamamoto M, Yoshida T and Numazawa S: Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia. Arterioscler Thromb Vasc Biol 33: 760-768, 2013.
98. Kaur B, Khwaja FW, Severson EA, et al: Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7: 134-153, 2005. (Pubitemid 40590514)
99. Kweider N, Fragoulis A, Rosen C, et al: Interplay between vascular endothelial growth factor (VEGF) and nuclear factor erythroid 2-related factor-2 (Nrf2): implications for preeclampsia. J Biol Chem 286: 42863-42872, 2011.
100. Kim TH, Hur EG, Kang SJ, et al: NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF1α. Cancer Res 71: 2260-2275, 2011.
101. Ji RC: Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett 346: 6-16, 2014.
102. Emara M and Allalunis-Turner J: Effect of hypoxia on angiogenesis related factors in glioblastoma cells. Oncol Rep 31: 1947-1953, 2014.
103. Marampon F, Gravina GL, Zani BM, et al: Hypoxia sustains glioblastoma radioresistance through ERKs/DNAPKcs/HIF1α functional interplay. Int J Oncol 44: 2121-2131, 2014.
104. Ji X, Wang H, Zhu J, et al: Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF1α. Int J Cancer 135: 574-584, 2014.
105. Ji X, Wang H, Zhu J, et al: Correlation of Nrf2 and HIF1α in glioblastoma and their relationships to clinicopathologic features and survival. Neurol Res 35: 1044-1050, 2013.
106. Shen H, Yang Y, Xia S, et al: Blockage of Nrf2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Esophagus: Sep 13, 2013 (Epub ahead of print).
107. Lee C, Park GH and Jang JH: Cellular antioxidant adaptive survival response to 6-hydroxydopamine-induced nitrosative cell death in C6 glioma cells. Toxicology 283: 118-128, 2011.
108. Meisen WH and Kaur B: How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma? Expert Rev Neurother 13: 341-343, 2013.
109. Al-Huseini LM, Aw Yeang HX, Sethu S, et al: Nuclear factor-erythroid 2 (NFE2) p45-related factor-2 (Nrf2) modulates dendritic cell immune function through regulation of p38 MAPK-cAMP-responsive element binding protein/activating transcription factor 1 signaling. J Biol Chem 288: 22281-22288, 2013.
110. Thimmulappa RK, Lee H, Rangasamy T, et al: Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 116: 984-995, 2006.
111. + T cells. J Immunol 188: 1630-1637, 2012.
112. Foresti R, Bains SK, Pitchumony TS, et al: Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol Res 76: 132-148, 2013.
113. Limonciel A and Jennings P: A review of the evidence that ochratoxin A is an Nrf2 inhibitor: implications for nephrotoxicity and renal carcinogenicity. Toxins 6: 371-379, 2014.